Proteostasis Therapeutics Announces Appointment of Mark J. Enyedy as Chief Executive Officer

Proteostasis Therapeutics Announces Appointment of Mark J. Enyedy as Chief Executive Officer
-Former President of Genzyme's Transplant, Oncology and MS Divisions Will Lead Emerging Company in Next Phase of Growth-

CAMBRIDGE, Mass., Oct 20, 2011 (BUSINESS WIRE) -- Proteostasis Therapeutics today announced the appointment of Mark J. Enyedy as Chief Executive Officer. Mr. Enyedy joins Proteostasis after serving 15 years at Genzyme Corporation, most recently as President of the Transplant, Oncology and Multiple Sclerosis divisions. Mr. Enyedy has also been elected to the Proteostasis Board of Directors.

"Proteostasis has built an innovative and productive platform focused on protein folding, trafficking and degradation. Working with the leading scientists in the emerging field of protein homeostasis, the Company has applied this platform to define key pathways driving the onset and progression of a range of genetic and neurodegenerative disorders," said Mr. Enyedy. "I look forward to working with the talented team and external collaborators that Proteostasis has assembled to develop novel therapies to improve the lives of patients suffering from these debilitating diseases."

"Mark's background in building businesses in multiple therapeutic areas at a large, yet entrepreneurial company will be invaluable to Proteostasis," said Chris Mirabelli, Chairman of the Proteostasis Board of Directors. "His experience in operations, R&D management and business development is an ideal fit for a company of our stage."

Prior to joining Proteostasis, Mr. Enyedy served in a number of roles of increasing responsibility within Genzyme. As a member of Genzyme's senior management team, he was responsible for developing and executing the strategic plan to build the commercial oncology business, leading to significant revenue growth and operations in more than 50 countries. Additionally, he oversaw the execution of Genzyme's largest R&D program, directed two global product launches, led multiple M&A transactions, and chaired the corporate Portfolio Management Committee. Prior to joining general management, Mr. Enyedy served as Vice President, Business Development and Director, Business Development for the Oncology division, where he completed more than 20 licensing and partnering transactions. Before joining Genzyme, Mr. Enyedy served as an associate in the business law department at Palmer & Dodge. Mr. Enyedy received his J.D. from Harvard Law School and his B.S. from Northeastern University.

Please click here to view and download a headshot of Mr. Enyedy.

About Proteostasis Therapeutics

Proteostasis Therapeutics is developing "Proteostasis Regulators," small molecule drugs that restore proper protein function or remove misfolded and aggregated proteins to improve outcomes for patients with neurodegenerative and genetic disorders. The Proteostasis Network is the cellular machinery responsible for protein folding, trafficking and clearance, and can become imbalanced by the cumulative effects of aging, disease, genetics and environmental factors. www.proteostasis.com

SOURCE: Proteostasis Therapeutics

MacDougall Biomedical Communications
Jennifer Conrad, 781-235-3060

 

 

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.